natgillin/translations-raw huggingface dataset:
The capsule shell contains gelatin, glycerol, d-sorbitol and sorbitans solution, titanium dioxide and red printing ink.
Ovojnica kapsule vsebuje: želatino, glicerol, raztopino d- sorbitola in sorbitanov, titanov dioksid in rdeče črnilo za tisk.
The capsule shell contains gelatin, red iron oxide, propylene glycol, purified water, ‘sorbitol special-glycerin blend’ (d-sorbitol, 1,4 sorbitan, mannitol and glycerin) and titanium dioxide.
Ovoj kapsule vsebuje želatino, rdeči železov oksid, propilenglikol, prečiščeno vodo, 'mešanico posebnega sorbitola in glicerola' (d-sorbitol, 1,4 sorbitan, manitol in glicerol) in titanov dioksid.
The capsule shell contains gelatin, titanium dioxide (E171) and either brilliant blue FCF (E133) for Wilzin 25 mg, or sunset yellow FCF (E110) for Wilzin 50 mg.
Ovojnica kapsule vsebuje želatino, titanov dioksid (E171) in bodisi briljantno modro FCF (E133) pri Wilzinu 25 mg ali sončno rumeno FCF (E110) pri Wilzinu 50 mg.
The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132) and yellow iron oxide (E172) and white and black ink.
Ovojnica kapsule vsebuje: želatino, titanov dioksid (E171), indigotin (E132), rumeni železov oksid (E172) ter belo in črno črnilo;
The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132), brilliant blue FCF (E133), and white ink.
Ovojnica kapsule vsebuje: želatino, titanov dioksid (E171), indigotin (E132), briljantno modro FCF (E133) in belo črnilo.
The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132), yellow iron oxide (E172) and white ink.
Ovojnica kapsule vsebuje: želatino, titanov dioksid (E171), indigotin (E132), rumeni železov oksid (E172) in belo črnilo.
The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132), yellow iron oxide (E172), erythrosin (E127) and white ink.
Ovojnica kapsule vsebuje: želatino, titanov dioksid (E171), indigotin (E132), rumeni železov oksid (E172), eritrozin (E127) in belo črnilo.
The capsule shell contains: gelatin, titanium dioxide (E171), shellac, propylene glycol, potassium hydroxide, black iron oxide (E172).
Ovojnica kapsule vsebuje: želatino, titanov dioksid (E171), šelak, propilenglikol, kalijev hidroksid, črni železov oksid (E172).
The capsule shell contains: gelatine, sodium laurilsulfate, titanium dioxide (E171) and silicon dioxide (E551).
Ovojnica kapsule vsebuje: želatino, natrijev lavrilsulfat, titanov dioksid (E171) in silicijev dioksid (E551).
The capsule shell contains: gelatine, sodium laurilsulfate, titanium dioxide (E171) and silicon dioxide.
Ovojnica kapsule vsebuje: želatino, natrijev lavrilsulfat, rumeni železov oksid (E172), titanov dioksid (E171) in silicijev dioksid (E551).
The capsule shell contains: gelatine, sodium laurilsulfate, yellow iron oxide (E172) and silicon dioxide (E551).
Ovojnica kapsule vsebuje: želatino, natrijev lavrilsulfat, rumeni železov oksid (E172) in silicijev dioksid (E551).
The capsule shell contains: gelatine, sodium laurilsulfate, yellow iron oxide (E172) and silicon dioxide.
Ovojnica kapsule vsebuje: želatino, natrijev lavrilsulfat, rumeni železov oksid (E172), titanov dioksid (E171) in silicijev dioksid (E551).
The capsule shell contains: gelatine, sodium laurilsulfate, yellow iron oxide (E172), titanium dioxide (E171) and silicon dioxide (E551).
Ovojnica kapsule vsebuje: želatino, natrijev lavrilsulfat, rumeni železov oksid (E172), titanov dioksid (E171) in silicijev dioksid (E551).
The capsule shell for the 20 mg capsule contains gelatin and titanium dioxide (E171).
Ovojnica kapsul 20 mg vsebuje želatino in titanov oksid (E 171).
The capsule shell for the 30 mg capsule contains gelatin, titanium dioxide (E171), red iron oxide (E172) and yellow iron oxide (E172).
Ovojnica kapsul 30 mg vsebuje želatino, titanov oksid (E 171), rdeči železov oksid (E 172) in rumeni železov oksid (E 172).
The capsule shell for the 40 mg capsule contains gelatin, titanium dioxide (E171) and yellow iron oxide (E172).
Ovojnica kapsul 40 mg vsebuje želatino, titanov oksid (E 171) in rumeni železov oksid (E 172).
The capsule shell for the 5 mg and 10 mg capsules contains gelatin, titanium dioxide (E171) and red iron oxide (E172).
Ovojnica kapsul 5 mg in 10 mg vsebuje želatino, titanov oksid (E 171) in rdeči železov oksid (E 172).
The capsule shell for the 60 mg capsule contains gelatin, titanium dioxide (E171) and yellow iron oxide (E172).
Ovojnica kapsul 60 mg vsebuje želatino, titanov oksid (E 171) in rumeni železov oksid (E 172).
The capsule shell is composed of gelatin, titanium dioxide (E171), iron oxide yellow (E172) and iron oxide red (E172).
Ovojnica kapsule vsebuje želatino, titanov dioksid (E171), rumeni železov oksid (E172), rdeči železov oksid (E172).
The capsule shell is made of gelatin, titanium dioxide (E171), erythrosine (E127), indigotin (E132).
Ovojnica kapsule je izdelana iz želatine, titanovega dioksida (E171), eritrozina (E127), indigotina (E132).
The capsule shell is made of gelatin, titanium dioxide (E171).
Ovojnica kapsule je izdelana iz želatine in titanovega dioksida (E171).
The capsule shell is made of gelatin, which is harmless to humans if swallowed or inhaled.
Ovoj kapsule je izdelan iz želatine, ki ljudem ne škoduje, če jo zaužijejo ali vdihnejo.
The capsule should be swallowed whole with a glass of water during a meal.
Kapsule je treba pogoltniti cele z vodo, med obrokom.
The capsule should be swallowed whole with a glass of water, to ensure delivery to the stomach.
Celo kapsulo je treba pogoltniti s korazecem vode, da se zagotovi prehod v želodec.
The capsule should be swallowed whole with a glass of water, to ensure delivery to the stomach.
Celo kapsulo je treba pogoltniti s kozarcem vode, da se zagotovi prehod v želodec.
The capsule should be swallowed with water.
Kapsulo pogoltnite celo z vodo.
The capsule should be taken at least 30 minutes before a meal.
Kapsulo vzemite vsaj 30 minut pred obrokom.
The capsule(s) must be swallowed whole, and must not be chewed crushed or divided.
Bolnik mora kapsule pogoltniti cele in jih ne sme žvečiti, drobiti ali deliti.
The capsule(s) must be swallowed whole, and must not be chewed, crushed or divided.
Kapsulo oz. kapsule morate pogoltniti cele; ne smete jih žvečiti, drobiti ali deliti.
The capsules and oral solution can also be used for the treatment of dementia in adult patients with Parkinson’s disease.
Kapsule in orodisperzibilne tablete lahko uporabljamo tudi za zdravljenje demence pri odraslih bolnikih s Parkinsonovo boleznijo.
The capsules and oral solution can also be used for the treatment of dementia in adult patients with Parkinson’s disease.
Kapsule in peroralna raztopina se lahko uporabljajo tudi za zdravljenje demence pri odraslih bolnikih s Parkinsonovo boleznijo.
The capsules and oral solution can also be used for the treatment of dementia in adult patients with Parkinson’s disease.
Kapsule in peroralna raztopina se lahko uporabljajo tudi zdravljenje demence pri odraslih bolnikih s Parkinsonovo boleznijo.
The capsules and oral solution can also be used for the treatment of dementia in adult patients with Parkinson’s disease.
Kapsule in peroralno raztopino lahko uporabljamo tudi za zdravljenje demence pri odraslih bolnikih s Parkinsonovo boleznijo.
The capsules and oral solution can also be used to treat mild to moderately severe dementia in patients with Parkinson’s disease.
Kapsule in peroralna raztopina se lahko uporabljajo tudi za zdravljenje blage do zmerno hude demence pri bolnikih s Parkinsonovo boleznijo.
The capsules and oral solution must be taken with food, but the tablets can be taken with or without food.
Kapsule in peroralna raztopina se morajo jemati s hrano, medtem ko se lahko tablete vzamejo s hrano ali brez nje.
The capsules are for inhalation use only and should not be swallowed.
Kapsule so namenjene samo uporabi z inhalatorjem in jih ne smete pogoltniti.
The capsules are not to be swallowed.
Kapsul ne smete pogoltniti.
The capsules are opaque pink and imprinted with ‘HYCAMTIN’ and ‘1 mg’.
Kapsule so opačne rožnate barve in označene s ‘HYCAMTIN’ in ‘1 mg’.
The capsules are opaque white to yellowish white and imprinted with ‘HYCAMTIN’ and ‘0.25 mg’.
Kapsule so motne bele do rumenkasto bele barve in označene s ‘HYCAMTIN’ in ‘0.25 mg’.
The capsules are printed with inks containing cochineal carminic acid (E120), indigo carmine (E132), and titanium dioxide (E171).
Kapsule so potiskane s črnili, ki vsebujejo škrlatno karminsko kislino (E120), indigotin (E132) in titanov dioksid (E171).
The capsules are printed with printing ink containing indigo carmine (E 132).
Kapsule so potiskane s tiskarskim črnilom, ki vsebuje indigo karmin (E 132).
The capsules are printed with printing ink containing titanium dioxide (E 171), indigo carmine (E 132) and iron oxide (E 172).
Kapsule so potiskane s tiskarskim črnilom, ki vsebuje titanov dioksid (E 171), indigo karmin (E 132) in železov oksid (E 172).
The capsules are provided in blisters and are available in packs containing 40 capsules or in multipacks containing 150 capsules (3 packs of 50).
Kapsule so pakirane v pretisnih omotih in so na voljo v pakiranjih, ki vsebujejo 40 kapsul in v skupnih pakiranjih, ki vsebujejo 150 kapsul (3 pakiranja po 50 kapsul).
The capsules are provided in packs.
Kapsule so na voljo v pakiranjih.
The capsules are semi-translucent white and coded ‘CRIXIVAN 200 mg’ on them in blue.
Kapsule so polprozorne, bele, z oznako na kapsuli ‘CRIXIVANTM 200 mg’ v modri barvi.
The capsules are semi-translucent white and coded ‘CRIXIVAN 400 mg’ on them in green.
Kapsule so polprozorne, bele, z oznako na kapsuli ‘CRIXIVANTM 400 mg’ v zeleni barvi.
The capsules are semi–translucent white and coded ‘CRIXIVAN 400 mg’ in green.
Kapsule so polprosojne, bele, z oznako ‘CRIXIVAN 400 mg’ zelene barve.
The capsules are semi–translucent white and coded ‘CRIXIVAN ™ 200 mg’ in blue.
Kapsule so polprosojne, bele, z oznako ‘CRIXIVAN 200 mg’ modre barve.
The capsules are supplied in aluminium blister packs of 10, 30, 60, or 90 capsules.
Kapsule so na voljo v aluminiastih pretisnih omotih, pakiranih po 10, 30, 60 ali 90 kapsul.
The capsules are supplied in aluminium blister packs of 30 or 90 capsules.
Kapsule so na voljo v aluminiastih pretisnih omotih, pakiranih po 30 ali 90 kapsul.
The capsules are supplied in Polyamide-Aluminium-PVC/aluminium blister packs containing 30, 60, or 90 capsules, and in opaque white plastic bottles containing either 14, 30, 60 or 90 capsules.
Kapsule so na voljo v pretisnih omotih iz poliamida- aluminija-PVC/aluminija, ki vsebujejo 30, 60 in 90 trdih kapsul, in v neprozornih belih plastenkah s 14, 30, 60 ali 90 kapsulami.
The capsules are transparent and orange and contain a white powder.
Kapsule so prozorne in oranžne barve ter vsebujejo bel prašek.
The capsules come in blisters of polyamide/aluminium/PVC with a push through aluminium foil lidding in cartons of 30 capsules.
Kapsule so na voljo v pretisnih omotih iz poliamida/aluminija/PVC, prekritih z aluminijevo folijo za predrtje, v kartonskih škatlah s po 30 kapsulami.
The capsules contain a white to off white powder.
Kapsula vsebuje bel do belkast prašek.
The capsules contain soya lecithin.
Kapsule vsebujejo sojin lecitin.
The capsules have a pink opaque coloured body marked “150 mg” and a grey cap marked "VISMO” in black edible ink.
Kapsule imajo neprozorno telo rožnate barve z oznako "150 mg" in siv pokrovček, na katerem je s črnim užitnim črnilom izpisana oznaka "VISMO".
The capsules have a transparent yellow cap and natural transparent body.
Kapsule imajo prozoren rumen pokrovček in brezbarvno prozorno telo.
The capsules must always be stored in the blister to protect from moisture and only removed immediately before use.
Za zagotovitev zaščite pred vlago je treba kapsule vedno shranjevati v pretisnem omotu in jih vzeti iz njega šele tik pred uporabo.
The capsules must be taken on an empty stomach and no food should be eaten for at least two hours before and two hours after the dose is taken (see section 5.2).
Kapsule je treba vzeti na prazen želodec, bolnik ne sme zaužiti nobene hrane najmanj dve uri pred odmerjanjem zdravila in najmanj dve uri po njem (glejte poglavje 5.2).
The capsules should be administered orally once daily at the same time every day.
Kapsule je treba vzeti peroralno enkrat na dan, in sicer vsak dan ob istem času.
The capsules should be swallowed whole with a glass of water, without eating anything for two hours before and one hour after each dose.
Kapsule je treba pogoltniti cele s kozarcem vode, dve uri prej in eno uro po vsakem odmerku pa bolnik ne sme ničesar pojesti.
The capsules should be swallowed whole without food but with water one hour before or two hours after a meal.
Kapsule je treba eno uro pred obrokom ali dve uri po njem pogoltniti cele z nekaj vode, vendar brez hrane.
The capsules should be taken at the same time each day and should be continued for as long as the disease improves or remains stable and the side effects are tolerable.
Zdravilo je treba vzeti vsak dan ob istem času in zdravljenje nadaljevati, dokler se bolnikovo stanje izboljšuje ali ostaja stabilno in so neželeni učinki znosni.
The capsules should not be chewed.
Kapsul ne smete žvečiti.
The capsules should remain in the blister until you need to use them.
Kapsule do uporabe pustite v pretisnem omotu.
The capsules should remain in the capsule card until you need to use them.
Kapsule do uporabe pustite v tablici s kapsulami.
The carbon dioxide diffuses into the blood vessels.
Ogljikov dioksid preide v krvne žile.
The carbon dioxide which is liberated diffuses into the blood vessels and is transported as bicarbonate to the lungs where it is then liberated as 13CO2 in exhaled air.
Sproščen ogljikov dioksid difundira v krvne žile in se prenese kot bikarbonat v pljuča, kjer se sprosti kot 13CO2 v izdihanem zraku.
The carcinogenic potential of dexrazoxane has not been investigated, however, razoxane (the racemic mixture of dexrazoxane and levrazoxane) has been reported to be associated with the development of secondary malignancies in mice (lymphoid neoplasms) and rats (uterine carcinomas) after administration for a prolonged period of time.
Karcinogenega potenciala deksrazoksana še niso raziskali, vendar je dolgoročno dajanje razoksana (racemno zmes deksrazoksana in levrazoksana), povezano s pojavom sekundarnih malignih tvorb pri miših (limfatične neoplazme) in podganah (maternični karcinomi).
The carcinogenic potential of methoxy polyethylene glycol-epoetin beta has not been evaluated in long-term animal studies.
Kancerogenega potenciala metoksipolietilenglikol epoetin beta v dolgoročnih raziskavah na živalih niso ocenjevali.
The Card informs patients of the risk of severe hepatic injury, and its possible symptoms, so that they are aware of situations in which they should contact a healthcare professional in a timely manner.
Opozorilna kartica bolnike obvešča o tveganju za hude poškodbe jeter in o možnih simptomih, z namenom, da spoznajo situacije, v katerih se morajo pravočasno obrniti na zdravstvenega delavca.
The Card reminds patients about key symptoms that need to be reported immediately to the physician/nurse.
Kartica bolnike spomni na ključne simptome, o katerih morajo takoj obvestiti zdravnika/medicinsko sestro.
The cardiac function of the patients treated concomitantly with Myocet and trastuzumab must be appropriately monitored as described below.
Delovanje srca bolnic, sočasno zdravljenih z zdravilom Myocet in trastuzumabom je treba ustrezno nadzirati, kot je opisano spodaj.
The cardiac safety profile for the dosing schedule recommended for both breast and ovarian cancer (50 mg/m2) is similar to the 20 mg/m2 profile in patients with AIDS-KS (see section 4.8).
Kardialni varnostni profil zdravila pri režimu odmerjanja, priporočenem za rak dojk ali rak jajčnikov (50 mg/m2), je podoben kot pri odmerjanju 20 mg/m2 za bolnike, ki imajo z aidsom povezan Kaposijev sarkom (glejte poglavje 4.8).
The cardiovascular status of patients should be evaluated and cardiovascular risk factors monitored and actively managed during Tasigna therapy according to standard guidelines.
Oceniti je treba bolnikov srčnožilni status in tekom zdravljenja z zdravilom Tasigna redno spremljati dejavnike srčnožilnega tveganja in jih obravnavati v skladu s standardnimi smernicami.
The carer should stop treatment and seek advice from the prescriber in the event of:
Skrbnik mora prekiniti zdravljenje in se posvetovati z zdravnikom, ki je predpisal zdravilo, v primeru:
The carrier protein and the adjuvant both help to stimulate a better response.
Nosilna beljakovina in adjuvans pomagata spodbuditi boljši odziv.
The cartilage cells are then grown and
Hrustančne celice se nato vzgojijo
The carton also contains, in a clear polyethylene wrap, a 5 ml graduated oral syringe and a Press-In Bottle adapter (PIBA).
Škatla vsebuje tudi prozoren polietilenski ovoj z graduirano 5-ml peroralno brizgo in nastavek za peroralno brizgo.
The carton contains 1 bottle.
Škatla vsebuje eno steklenico.
The carton contains 7, 28, 30 or 84 (multipack containing 2 packs of 42) transdermal patches, individually sealed in sachets.
Škatla vsebuje 7, 28, 30 ali 84 (večkratno pakiranje vsebuje 2 pakiranji po 42) transdermalnih obližev, posamezno pakiranih v zaščitne vrečke.
The carton contains 7, 28, 30 or 84 (multipack containing 2 packs of 42) transdermal patches, individually sealed in sachets.
Škatla vsebuje 7, 28, 30, ali 84 (večkratno pakiranje vsebuje 2 pakiranji po 42) transdermalnih obližev, posamezno pakiranih v zaščitne vrečke.
The carton contains a package leaflet with the full instructions for use and handling.
Škatla vsebuje navodilo za uporabo z natančnimi navodili za uporabo in rokovanje.
The carton contains a package leaflet with the full instructions for use and handling.
Škatla vsebuje navodilo za uporabo, ki obsega popolna navodila za uporabo in ravnanje.
The carton contains one blister of one tablet.
Ovojnina vsebuje en pretisni omot z eno tableto.
The carton contains one bottle.
Škatla vsebuej eno steklenico.
The carton contains the following items that you will need to administer the medicine:
Škatla vsebuje naslednje predmete, ki jih boste potrebovali za dajanje zdravila:
The cartridge (Penfill) is designed to be used with Novo Nordisk delivery systems (durable devices for repeated use not included in the pack) and NovoFine/NovoTwist injection needles up to a length of 8 mm.
Injekcijski vložek (Penfill) je namenjen za uporabo s sistemi za dajanje insulina Novo Nordisk (trajne naprave za večkratno uporabo, ki niso vključene v pakiranje) in injekcijskimi iglami NovoFine/NovoTwist, dolžine do 8 mm.
The cartridge (Penfill) is designed to be used with Novo Nordisk delivery systems (durable devices for repeated use not included in the pack) and NovoFine/NovoTwist injection needles up to a length of 8 mm.
Vložek (Penfill) je namenjen za uporabo s sistemi za dajanje insulina družbe Novo Nordisk (trajne naprave za večkratno uporabo, ki niso priložene posameznemu pakiranju) in injekcijskimi iglami NovoFine/NovoTwist, dolžine do 8 mm.
The cartridge (Penfill) is for use by one person only.
Injekcijski vložek (Penfill) je namenjen uporabi ene same osebe.
The cartridge (Penfill) is for use by one person only.
Vložek (Penfill) je namenjen uporabi ene same osebe.
The cartridge contains a glass ball to facilitate resuspension.
V injekcijskem vložku je steklena kroglica, ki olajša resuspendiranje.
The cartridge in use in the insulin pen must not be stored in a refrigerator.
Vložka, ki ga uporabljate, ne smete shranjevati v hladilniku.
The cartridge in use in the insulin pen must not be stored in the refrigerator.
Vložka, ki ga uporabljate (v insulinskem injekcijskem peresniku), ne smete shranjevati v hladilniku.
The cartridge in use must not be stored in a refrigerator.
Vložkov, ki jih uporabljate, ne smete shranjevati v hladilniku.
The cartridge in your Byetta pen may not have enough liquid to deliver a full dose.
Vložek vašega injekcijskega peresnika Byetta morda ne vsebuje zadosti tekočine za dajanje celotnega odmerka.
The cartridge in-use (in the insulin pen) or carried as a spare may be stored for a maximum of 4 weeks not above 25°C and away from direct heat or direct light.
Vložek, ki ga uporabljate (v injekcijskem peresiku) ali ga imate pri sebi za rezervo, lahko shranjujete največ 4 tedne pri temperaturi do 25°C in zaščiteno pred neposredno toploto ali svetlobo.
The cartridge in-use (in the insulin pen) or carried as a spare may be stored for a maximum of 4 weeks not above 25°C and away from direct heat or direct light.
Vložek, ki ga uporabljate ali ga imate pri sebi za rezervo lahko shranjujete največ 4 tedne pri temperaturi do 25°C in zaščiteno pred neposredno toploto ali svetlobo.
The cartridge in-use (in the insulin pen) or carried as a spare may be stored for a maximum of 4 weeks not above 25°C and away from direct heat or direct light.
Vložek, ki ga uporabljate ali ga imate pri sebi za rezervo, lahko shranjujete največ 4 tedne pri temperaturi do 25°C in zaščiteno pred neposredno toploto ali svetlobo.
The cartridge in-use in the pen may be stored for a maximum of 28 days not above 25 °C.
Vložek v injekcijskem peresniku lahko shranjujete največ 28 dni pri temperaturi do 25 °C.
The cartridge in-use in the pen may be stored for a maximum of 28 days.
Vložek v injekcijskem peresniku se lahko shranjuje največ 28 dni.
The cartridge in-use must not be stored in a refrigerator.
Vložka, ki ga uporabljate (v insulinskem injekcijskem peresniku) ne smete shranjevati v hladilniku.
The cartridge in-use must not be stored in a refrigerator.
Vložka, ki ga uporabljate (v insulinskem injekcijskem peresniku), ne smete shranjevati v hladilniku.
The cartridge in-use must not be stored in a refrigerator.
Vložka, ki ga uporabljate ne smete shranjevati v hladilniku.
The cartridge in-use must not be stored in a refrigerator.
Vložka, ki ga uporabljate, ne smete shranjevati v hladilniku.
The cartridge is sealed in a disposable pen injector.
Vložek je zapečaten v injekcijski peresnik za enkratno uporabo.
The cartridge is sealed in a disposable pre-filled pen.
Vložek je zavarjen v napolnjeni injekcijski peresnik za enkratno uporabo.
The cartridge is to be used either with the RebiSmart electronic injection device or the RebiSlide manual pen injector device.
Vložek uporabite bodisi z elektronskim pripomočkom za injiciranje RebiSmart ali z ročnim injekcijskim peresnikom RebiSlide.
The cartridge must not be refilled.
Injekcijskega vložka se ne sme znova polniti.
The cartridge should be inspected before use.
Vložek pred uporabo preglejte.
The cartridges come in packs of 5 cartridges or a multipack of 2 x 5 cartridges.
Vložki so na voljo v pakiranju po 5 vložkov ali kot večje pakiranje 2 x 5 vložkov.
The cartridges come in packs of 5 cartridges or a multipack of 2 x 5 cartridges.
Vložki so na voljo v pakiranju po 5 vložkov ali v večjem pakiranju 2 x 5 vložkov.
The cartridges for OptiClik are to be used in conjunction OptiClik only and as recommended in the information provided by the device manufacturer.
Vložki za injekcijski peresnik OptiClik se uporabljajo samo skupaj z injekcijskim peresnikom OptiClik in po navodilih izdelovalca injekcijskega peresnika.
The cartridges for OptiClik are to be used in conjunction OptiClik only and as recommended in the information provided by the device manufacturer.
Vložki za injekcijski peresnik OptiClik se uporabljajo samo skupaj z injekcijskim peresnikom OptiClik in po navodilih izdelovalca peresnika.
The cartridges for OptiClik are to be used in conjunction with OptiClik only and as recommended in the information provided by the device manufacturer.
Vložke OptiClik uporabljajte samo z OptiClikom in po navodilih izdelovalca injekcijskega peresnika.
The cartridges for OptiClik are to be used in conjunction with OptiClik only, and as recommended in the information provided by the device manufacturer.
Vložke za OptiClik uporabljajte samo z OptiClikom in po navodilih izdelovalca injekcijskega peresnika.